MX2021004027A - Composiciones de microparticulas inyectables de naltrexona de accion prolongada. - Google Patents
Composiciones de microparticulas inyectables de naltrexona de accion prolongada.Info
- Publication number
- MX2021004027A MX2021004027A MX2021004027A MX2021004027A MX2021004027A MX 2021004027 A MX2021004027 A MX 2021004027A MX 2021004027 A MX2021004027 A MX 2021004027A MX 2021004027 A MX2021004027 A MX 2021004027A MX 2021004027 A MX2021004027 A MX 2021004027A
- Authority
- MX
- Mexico
- Prior art keywords
- naltrexone
- microparticle compositions
- injectable long
- injectable
- acting naltrexone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Botany (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a sistemas de administración de micropartículas de liberación sostenida de naltrexona para el tratamiento de enfermedades mejoradas por la naltrexona. El sistema de administración de micropartículas inyectables incluye naltrexona encapsulada en micropartículas biodegradables administradas en un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745805P | 2018-10-15 | 2018-10-15 | |
PCT/KR2019/013535 WO2020080806A1 (en) | 2018-10-15 | 2019-10-15 | Injectable long-acting naltrexone microparticle compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004027A true MX2021004027A (es) | 2021-08-11 |
Family
ID=70162021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004027A MX2021004027A (es) | 2018-10-15 | 2019-10-15 | Composiciones de microparticulas inyectables de naltrexona de accion prolongada. |
Country Status (16)
Country | Link |
---|---|
US (1) | US11000479B2 (es) |
EP (1) | EP3866765B1 (es) |
JP (1) | JP7262576B2 (es) |
KR (1) | KR102639578B1 (es) |
CN (1) | CN113164395A (es) |
AU (1) | AU2019362730B2 (es) |
BR (1) | BR112021006747A2 (es) |
CA (1) | CA3112938C (es) |
FI (1) | FI3866765T3 (es) |
HR (1) | HRP20240356T1 (es) |
LT (1) | LT3866765T (es) |
MX (1) | MX2021004027A (es) |
PT (1) | PT3866765T (es) |
RS (1) | RS65300B1 (es) |
WO (1) | WO2020080806A1 (es) |
ZA (1) | ZA202102739B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022394933A1 (en) * | 2021-11-18 | 2024-05-09 | Inventage Lab Inc. | Sustained-release injectable composition containing naltrexone and method for preparing same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
US6306425B1 (en) | 1999-04-09 | 2001-10-23 | Southern Research Institute | Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US7914804B2 (en) | 2000-09-01 | 2011-03-29 | Palmaya Pty Ltd | Slow release pharmaceutical preparation and method of administering same |
US7157102B1 (en) | 2002-05-31 | 2007-01-02 | Biotek, Inc. | Multi-layered microcapsules and method of preparing same |
CN1166360C (zh) | 2002-11-07 | 2004-09-15 | 上海医药工业研究院 | 一种纳曲酮长效注射微球组合物及制备方法和应用 |
AU2004245057B2 (en) | 2003-06-04 | 2008-07-31 | Alkermes Pharma Ireland Limited | Polymorphic forms of naltrexone |
CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
ATE426399T1 (de) * | 2004-02-23 | 2009-04-15 | Euro Celtique Sa | Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen |
US7919499B2 (en) | 2004-04-22 | 2011-04-05 | Alkermes, Inc. | Naltrexone long acting formulations and methods of use |
MX2007001760A (es) * | 2004-08-12 | 2007-07-24 | Quest Pharmaceutical Services | Composiciones farmaceuticas para la distribucion de liberacion controlada de compuestos biologicamente activos. |
CN100379420C (zh) * | 2006-09-19 | 2008-04-09 | 深圳市思沃生命科学技术有限公司 | 一种用于戒毒的长效缓释制剂及其制备方法和用途 |
CN100548278C (zh) * | 2007-05-17 | 2009-10-14 | 中国人民解放军军事医学科学院生物工程研究所 | 一种提高纳曲酮微球包封率的制备方法 |
WO2009058147A1 (en) * | 2007-10-31 | 2009-05-07 | Celonova Biosciences, Inc. | Loadable polymeric particles for therapeutic use in erectile dysfunction |
CN101612437B (zh) * | 2009-01-09 | 2011-09-14 | 清华大学 | 纳曲酮微球-水凝胶骨架原位埋植给药系统 |
CN101700226A (zh) * | 2009-03-26 | 2010-05-05 | 海南凤凰国际药物研究院 | 一种不需要包衣的纳曲酮长效缓释制剂及其制备方法 |
KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
SI3340968T1 (sl) | 2015-08-24 | 2022-10-28 | Rusan Pharma Limited | Implantabilne tablete naltreksona |
WO2018111851A1 (en) * | 2016-12-12 | 2018-06-21 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
-
2019
- 2019-10-15 AU AU2019362730A patent/AU2019362730B2/en active Active
- 2019-10-15 KR KR1020217014773A patent/KR102639578B1/ko active IP Right Grant
- 2019-10-15 WO PCT/KR2019/013535 patent/WO2020080806A1/en active Application Filing
- 2019-10-15 HR HRP20240356TT patent/HRP20240356T1/hr unknown
- 2019-10-15 EP EP19874338.7A patent/EP3866765B1/en active Active
- 2019-10-15 CA CA3112938A patent/CA3112938C/en active Active
- 2019-10-15 US US16/653,707 patent/US11000479B2/en active Active
- 2019-10-15 CN CN201980068008.2A patent/CN113164395A/zh active Pending
- 2019-10-15 BR BR112021006747-7A patent/BR112021006747A2/pt unknown
- 2019-10-15 MX MX2021004027A patent/MX2021004027A/es unknown
- 2019-10-15 RS RS20240326A patent/RS65300B1/sr unknown
- 2019-10-15 PT PT198743387T patent/PT3866765T/pt unknown
- 2019-10-15 JP JP2021521011A patent/JP7262576B2/ja active Active
- 2019-10-15 FI FIEP19874338.7T patent/FI3866765T3/fi active
- 2019-10-15 LT LTEPPCT/KR2019/013535T patent/LT3866765T/lt unknown
-
2021
- 2021-04-23 ZA ZA2021/02739A patent/ZA202102739B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3866765B1 (en) | 2024-02-07 |
LT3866765T (lt) | 2024-04-25 |
JP7262576B2 (ja) | 2023-04-21 |
CA3112938A1 (en) | 2020-04-23 |
AU2019362730B2 (en) | 2022-10-20 |
EP3866765A1 (en) | 2021-08-25 |
US20200113835A1 (en) | 2020-04-16 |
HRP20240356T1 (hr) | 2024-06-07 |
FI3866765T3 (fi) | 2024-04-18 |
BR112021006747A2 (pt) | 2021-07-13 |
KR20210065190A (ko) | 2021-06-03 |
US11000479B2 (en) | 2021-05-11 |
WO2020080806A1 (en) | 2020-04-23 |
PT3866765T (pt) | 2024-04-17 |
CA3112938C (en) | 2023-08-15 |
RS65300B1 (sr) | 2024-04-30 |
JP2022511624A (ja) | 2022-02-01 |
CN113164395A (zh) | 2021-07-23 |
AU2019362730A1 (en) | 2021-05-13 |
EP3866765A4 (en) | 2022-06-29 |
KR102639578B1 (ko) | 2024-02-21 |
ZA202102739B (en) | 2023-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
PH12015501601A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2015009773A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
PH12015501596A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2015009785A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
MX2015009778A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
NZ599558A (en) | Dosing regimen associated with long-acting injectable paliperidone esters | |
PH12015502745A1 (en) | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | |
MX2013002725A (es) | Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco. | |
MD3310345T2 (ro) | Comprimată orodispersabilă ce conține estetrol | |
MX352176B (es) | Proceso para producir un material inorganico particulado. | |
MX2016000964A (es) | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. | |
ZA202102739B (en) | Injectable long-acting naltrexone microparticle compositions | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
MX353623B (es) | Sistema de suministro de farmaco. | |
PH12017502149A1 (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
MX2016004444A (es) | Microparticulas que comprenden gnrh hechas mediante pgss. | |
MX2016006738A (es) | Procedimiento para producir material particulado inorganico. | |
MX2022007315A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
MX2015011624A (es) | Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras. | |
MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
MX348595B (es) | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. | |
EP2588112A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
UA108865C2 (uk) | Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі |